Stress Urinary Incontinence Clinical Trial
Official title:
Effect of Kinesiotaping on Activation of Abdominal Muscles in Female Patients With Stress Urinary Incontinence
This study will be conducted to evaluate the effect of kinesiotaping on activation of abdominopelvic cavity for management of stress urinary incontinence females' patients.
Status | Not yet recruiting |
Enrollment | 40 |
Est. completion date | June 1, 2024 |
Est. primary completion date | May 1, 2024 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 30 Years to 50 Years |
Eligibility | Inclusion Criteria: 1. Women suffering from mild to moderate stress urinary incontinence, clinically diagnosed by the gynecologist. 2. Their ages will be ranged from 30-50 years old. 3. Their body mass index (BMI) will be ranged from (20-25 kg/m2). 4. They shouldn't have any musculoskeletal or neurological disorders. Exclusion Criteria: 1. Current pregnancy. 2. Malignant condition 3. History of acute infection 4. Neurological problem 5. Mental problem to prevent evaluation and cooperation 6. Having allergies to kinesiotaping 7. Having uncontrolled metabolic diseases like diabetes and thyroid disease. 8. Athletic females |
Country | Name | City | State |
---|---|---|---|
Egypt | Cairo University | Giza |
Lead Sponsor | Collaborator |
---|---|
Cairo University |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pelvic floor impact questionnaire- short form 7 (PFIQ-7) | It will be used to evaluate the efficacy of a particular therapy, and to compare bladder, bowel or vaginal symptoms severity for all females in both groups (A&B) before and after treatment. All of the items use the following response scale: 0, Not at all; 1, somewhat; 2, moderately; 3, quite a bit PFIQ-7 Score, Obtain the mean value for all of the answered items within the corresponding scale (possible value 0- 3) and then multiply by (100/3) to obtain the scale score (range 0-100). The final score is the sum of the scores from the 3 scales together to obtain the summary score (range 0-300). | 4 weeks | |
Primary | King's Health Questionnaire (KHQ) | The KHQ is a validated instrument for measuring the quality of life of women with urinary incontinence. This questionnaire consists of two parts and 32 items. The first part (21 items) contains two single-item questions that address General Health Perception and Incontinence Impact and the following seven multi-item domains: Role, Physical, and Social Limitations, Limitations in Personal Relationship, Emotional Problems, Sleep and Energy Disturbances associated with SUI, and Severity Measures for UI. The second part has an 11-item Symptom Severity Scale (SSS) that assesses the presence and severity of urinary symptoms. While the entire SSS is scored from 0 (best) to 30 (worst), the minimum possible score is 0 (best health) and the maximum possible score is 100 (worst health) for all other KHQ domains. | 4 weeks | |
Secondary | Assessment of pelvic floor muscle strength | The pelvic floor muscle strength will be assessed using a perineometer for all females in both groups (A&B) before and after treatment. Each participant will be positioned relaxed in supine with flexed, slightly abducted legs, where each participant will be asked to insert the probe that will be covered by condom and be lubricated with hypoallergic gel into her vaginal cavity, where 0.5-1 centimeter of the probe sustained visible outside of her introitus. Then each participant will be asked to squeeze by a maximum voluntary contraction in three repetitions, each will be last by 3 seconds, with 3 seconds rest in-between, Then, a 2-minutes rest break will be taken, followed by visible contraction of transversus abdominis muscle, as long without pelvic tilting. And will take the median of the three measures. | 4 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04829357 -
Post Market Clinical Follow-up Study on TVT ABBREVO® Continence System
|
||
Completed |
NCT05493735 -
Lidocaine for Pessary Check Pain Reduction
|
Phase 3 | |
Completed |
NCT04512053 -
A Phase 2 Study of TAS-303 in Female Patients With Stress Urinary Incontinence
|
Phase 2 | |
Active, not recruiting |
NCT06224335 -
Measurement of Intravaginal and Intra-abdominal Pressure and Pad Test During Sports Activities (SPORTVAGPRES)
|
||
Recruiting |
NCT05304312 -
The Role of Kegel Exercises Book to Improve Treatment in Stress Urinary Incontinence Women
|
N/A | |
Not yet recruiting |
NCT05527665 -
Sexual Fonction and Discomfort in Women After Midurethral Sling Surgery, Using PPSSQ
|
||
Not yet recruiting |
NCT04558762 -
Ten Years Follow-up After Insertion of a MUS (Mid Urethral Sling) Due to Stress Urinary Incontinence
|
||
Withdrawn |
NCT02524366 -
A Study of Transcorporal Versus Standard Artificial Urinary Sphincter Placement
|
N/A | |
Completed |
NCT01924728 -
Efficacy of Magnetic Stimulation for Stress Urinary Incontinence
|
N/A | |
Completed |
NCT01676662 -
Solace European Confirmatory Trial
|
N/A | |
Unknown status |
NCT01455779 -
Lyrette: Renewing Continence Objective and Subjective Efficacy Study
|
N/A | |
Terminated |
NCT01029106 -
Gynecare TVT Secur for the Management of Stress Urinary Incontinence (SUI)
|
N/A | |
Completed |
NCT01123096 -
Is the Cough Stress Test Equivalent to the 24 Hour Pad Test in the Assessment of Stress Incontinence?
|
N/A | |
Withdrawn |
NCT00573703 -
Laparoscopic Burch Colposuspension Versus Transobturatory Tape for the Treatment of Female Urinary Stress Incontinence
|
Phase 4 | |
Completed |
NCT01770691 -
Preliminary Performance Study of the New TIPI Device in the Prevention of Stress Urinary Incontinence
|
N/A | |
Completed |
NCT00234754 -
Trans-Obturator Tape Versus Trans-Vaginal Tape for Stress Urinary Incontinence in Women
|
N/A | |
Completed |
NCT00441454 -
Retropubic vs. Transobturator Tension-free Vaginal Tape
|
N/A | |
Completed |
NCT03985345 -
Prospective Evaluation of the Connected EMY Biofeedback Probe in the Management of Stress Urinary Incontinence.
|
N/A | |
Active, not recruiting |
NCT03671694 -
Laser Vaginal Treatment for SUI
|
N/A | |
Completed |
NCT04097288 -
Effects of Single Dose Citalopram and Reboxetine on Urethral and Anal Closure Function on Healthy Female Subjects
|
Phase 1 |